Altor and Florida Biologix in Cancer Therapy Pact

ALT-803 has demonstrated anti-tumor activities in various preclinical cancer models and could potentially make a life-changing difference for patients with solid and hematological tumors.

Altor BioScience and Florida Biologix will collaborate in the development of  ALT-803, an interleukin-15 (IL-15)-based immunotherapeutic, to the clinic as a novel cancer therapy.

ALT-803 has demonstrated anti-tumor activities in various preclinical cancer models and could potentially make a life-changing difference for patients with solid and hematological tumors, according to a joint statement.

Florida Biologix will manufacture ALT-803 for clinical studies planned for early 2012. Florida Biologix will conduct an engineering run, cGMP manufacturing including mammalian cell culture at 400 L scale and chromatographic purification, formulation and aseptic fill of the cytokine complex.